Revefenacin

Revefenacin

Clinical data
Trade names	Yupelri
AHFS/Drugs.com	Monograph
MedlinePlus	a619009
License data	US DailyMed: Revefenacin
Routes of administration	Inhalation
ATC code	R03BB08 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
CAS Number	864750-70-9
PubChem CID	11753673
DrugBank	DB11855
ChemSpider	9928376
UNII	G2AE2VE07O
KEGG	D10978
CompTox Dashboard (EPA)	DTXSID701027775
Chemical and physical data
Formula	C35H43N5O4
Molar mass	597.760 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
InChI InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43) Key:FYDWDCIFZSGNBU-UHFFFAOYSA-N

Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.^[1] It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.^[2]

Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.^[3]

Society and culture

Brand names

In some countries, Yupelri is marketed by Viatris after Upjohn merged with Mylan to create Viatris.^[4][5]

References

1. "Theravance Biopharma and Mylan Receive FDA Approval for Yupelri (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease" (Press release). Mylan. 9 November 2018. Archived from the original on 15 September 2019. Retrieved 17 January 2019.
2. Heo YA (January 2019). "Revefenacin: First Global Approval". Drugs. 79 (1): 85–91. doi:10.1007/s40265-018-1036-x. PMC 6445810. PMID 30560478.
3. Donohue JF, Kerwin E, Barnes CN, Moran EJ, Haumann B, Crater GD (May 2020). "Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis". BMC Pulmonary Medicine. 20 (1): 134. doi:10.1186/s12890-020-1156-4. PMC 7216337. PMID 32393215.
4. "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024 – via Business Wire.
5. "Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.